There are a number of misconceptions about the interaction between sunlight and skin. In this two part post we look at what we think are the top five most common sun and skin myths.
Myth 1: I can’t get sunburnt on a cloudy day (more…)
Top five sun and skin myths (part 1)
Thursday, February 2nd, 2012Low sunscreen use, high melanoma rates: a breakdown of the sunsmart message?
Tuesday, January 24th, 2012
It’s estimated that more than 9,000 Americans will die from melanoma this year and 76,000 new cases of the disease will be diagnosed. Melanoma, an aggressive skin cancer which can spread (metastasize) quickly to other parts of the body, is also the second most common form of cancer in young Americans (those aged 15-29).
Overexposure of skin to ultraviolet (UV) radiation significantly increases an individual’s risk of melanoma, particularly at a young age; just one severe sunburn in childhood can double the lifetime risk of melanoma. Sun protective measures such as clothing and sunscreen are seen as key to reducing melanoma risk. (more…)
Photoaging
Thursday, December 22nd, 2011
Young adults are the age group most likely to seek a tan, with research showing that people under the age of 29 – particularly women – are tanning most frequently, both in the sun and under solariums. Aside from the well-recognised risks of skin cancer, there is another consequence of this increased exposure to ultraviolet (UV) radiation of which many teens are not aware – photoaging. In short, all this UV exposure over time makes skin look older. (more…)
EPP results and clinical relevance
Friday, November 4th, 2011
A protoporphyrin IX molecule
Over recent months I have written several times of the need for Clinuvel to prove clinical relevance in our trials with the use of SCENESSE® (afamelanotide) in erythropoietic protoporphyria (EPP). In orphan populations the need to demonstrate how a novel drug assists in their daily activities and improve their lives is at the forefront of the regulators’ minds. And so it should be, after all the objective of the pharmaceutical industry is to develop drugs which address either disease or symptoms adequately and safely. The results the company released yesterday from our Phase II US study of the drug in EPP (CUV030) have given us important data towards demonstrating clinically relevant improvement of patients’ lives. (more…)
Children at greater risk of melanoma spreading
Tuesday, October 11th, 2011
A recent study of melanoma in children and young adults indicates that there may be greater risk of metastasis, or spread, of the cancer in younger patients. The study, conducted by researchers at Baltimore’s John Hopkins Children’s Center, involved analysis of 2008 SEER (Surveillance, Epidemiology, and End Results) data on melanoma cases from 2003 to 2008. A total of 717 children and 1368 adults, aged 20-24, were diagnosed during this time.
Investigators looked at patients who received biopsies of the sentinel lymph nodes (SLN; those nearby the initial tumour) and the number of those in whom the disease had spread to this site. It was found that, of those biopsied, children were more likely to have cancer cells which had infiltrated the removed lymph nodes (25%), indicating greater rates of metastases than in adult patients (14%). (more…)
Clinical relevance – the value of patient experiences
Friday, September 30th, 2011
Since 2006 Clinuvel has trialed SCENESSE® in a truly unique group of individuals: patients living with erythropoietic protoporphyria (EPP), a rare genetic blood disorder which causes an absolute intolerance to light.
EPP prevents patients from leading ‘normal’ lives, especially outdoors. It is one of the few diseases that manifest clinically with initially invisible symptoms which cause severe dermal pain for several days. This not only presents a challenge for diagnosis and treatment, but also for generating meaningful clinical trial results – those which are measurable numerically and are used by regulatory authorities to evaluate the efficacy of a drug in a patient population. Here, real life patient experiences during a trial can play an important role in providing clinical relevance and analysing hard data. (more…)
A coffee a day keeps skin cancer at bay? Look a little deeper…
Thursday, August 18th, 2011
We tweeted it earlier this week and it’s been run across numerous news sites: new research has suggested that coffee – or more specifically caffeine – can help reduce the risk of skin cancer. It’s a fascinating story and one which deserves further review.
The research, conducted across multiple US sites and supported by National Institutes of Health grants, sought to expand upon an existing understanding of the correlation between the intake of caffeinated beverages and a decrease in the incidence of non-melanoma skin cancers. (more…)
Cellular messaging leading to melanin production
Tuesday, June 7th, 2011Each cell within the body has one or more receptors; molecules on or within the cell to which other molecules, called ligands, bind. This binding causes a series of chemical reactions within the cell, called a ‘signaling pathway’. Signaling pathways are responsible for cellular responses, allowing other cells and external elements to alter how a cell functions. There are two types of ligands which bind to receptors: agonists, which then promote a response in the pathway, and antagonists, which lead to an alternate response. (more…)
Melanoma/Skin Cancer Detection and Prevention Month
Tuesday, May 3rd, 2011
May is Melanoma/Skin Cancer Detection and Prevention Month in the US, and with summer just around the corner in the northern hemisphere, this is a timely reminder of the dangers of unprotected UV exposure.
Skin cancer is one of the most common forms of cancer in America, with more than 3 million cases diagnosed each year and over 10,000 deaths from the disease. Worryingly, unlike most forms of cancer which are declining, skin cancer rates in America are on the rise. There are three common types of skin cancer – basal cell carcinoma, squamous cell carcinoma and melanoma. Of these, melanoma is the least common, and yet the most frequently lethal form. (more…)
Porphyrias: a disease grouping by cause, not symptoms
Monday, April 18th, 2011
Held biennially, the Porphyrins & Porphyrias conference (P&P) is the world’s largest gathering on the porphyrias – a group of metabolic disorders causing biochemical disruptions in the pathway of the body which synthesizes haem (heme).
As a result of each of these disruptions, the body presents with unique symptoms ranging from skin symptoms and phototoxicity – as those seen in erythropoietic protoporphyria and congenital erythropoietic porphyria – through to acute attacks of abdominal pain, seen most commonly in acute intermittent porphyria. In short, no two porphyrias are clinically identical yet they are discussed as a single group of disorders with a similar cause. As a matter of fact, there are eight variations of porphyrias, each with a specific clinical manifestation of disease. (more…)
